Under the Pa	aperwork Reduction Act of 1	995, no	persons are require	d to respond to a collection of information unle	ess it contains a valid OMB control num	ber.
	Substitute for form 1449/PTO				Complete if Known	Orna
	INFORMATION I	DISCLO	SURE	Application Number	10/788,410	(E)
	STATEMENT BY	APPLI	CANT	Filing Date	3/1/2004	MAY 2 1 2010 0
	Date Submitted: 1	May 21	2010	First Named Inventor	Robert MARTUZA et al.	TIAT L LUIV HI
	Date Jubilitied. 1	'iay E i	, 2010	Art Unit	1632	(Z) K/
(use as many sheets as necessary)			ecessary)	Examiner Name	Wu Cheng Winston SHEN	
Sheet	1	of	1	Attorney Docket Number	066683-0198	PADEMA

_	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
	No.1	Number-Kind Code ² (<i>if known</i>) MM-DD-YYYY			Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te.
	G1	JP 8-127542	5/21/1996			Yes
	<u> </u>					

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	country T ⁶	
	G2	Japanese Office Action Application No. 2000-506984 dated March 29, 2010. (English Translation)		
	G3	Alessia MARTINOTTI et al., "CD4 T cells inhibit <i>in vivo</i> the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes", Eur. J. Immunol. 1995, 25:137—146.		
	G4	Glenn DRANOFF et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 3539—3543, April 1993.		

Examiner Signature	 ·	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.